TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Psychoeducation: Efficacy in Child Mood Disorders
Brief Summary: The purpose of this study is to evaluate the effectiveness of a Multifamily Psychoeducation Group for the families of children with mood disorders.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT), Drug: Drug therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Drug therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug therapy; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2
D: Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Brief Summary: This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.


Options:
A: Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg
B: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
C: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
D: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Brief Summary: This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.


Options:
A: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
B: Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
D: Arm Label: DAC HYP; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Other: Caffeine, Drug: S-warfarin, Other: Vitamin K, Drug: Omeprazole, Drug: Dextromethorphan, Biological: BIIB019 (Daclizumab) | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Caffeine; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: S-warfarin; Assigned to Arm(s): DAC HYP | Intervention Type: OTHER; Name: Vitamin K; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): DAC HYP | Intervention Type: DRUG; Name: Dextromethorphan; Assigned to Arm(s): DAC HYP | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab); Assigned to Arm(s): DAC HYP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Brief Summary: This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
D: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer
Brief Summary: The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer.

TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells.

TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: 5-FU & LV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: XELOX or modified FOLFOX-6; Type: EXPERIMENTAL; Interventions: Drug: Leucovorin, Drug: OXALIPLATIN, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: OXALIPLATIN; Assigned to Arm(s): XELOX or modified FOLFOX-6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 5-FU & LV, XELOX or modified FOLFOX-6
C: Intervention Type: GENETIC; Name: TNFerade; Assigned to Arm(s): N/A
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Brief Summary: This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.


Options:
A: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
B: Intervention Type: DRUG; Name: TLK286; Assigned to Arm(s): N/A
C: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
D: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child/Adolescent Anxiety Multimodal Treatment Study
Brief Summary: This randomized, controlled trial compared the efficacy of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders.


Options:
A: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
B: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coping Cat cognitive-behavioral therapy for anxious youth; Assigned to Arm(s): CBT
C: Arm Label: Usual Care Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: psychotherapy | Arm Label: Standard Manual Treatment (SMT); Type: EXPERIMENTAL; Interventions: Behavioral: evidence-based treatment | Arm Label: Modular Maual Treatment (MMT); Type: EXPERIMENTAL; Interventions: Behavioral: modular evidence-based treatment | Intervention Type: BEHAVIORAL; Name: psychotherapy; Assigned to Arm(s): Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: evidence-based treatment; Assigned to Arm(s): Standard Manual Treatment (SMT) | Intervention Type: BEHAVIORAL; Name: modular evidence-based treatment; Assigned to Arm(s): Modular Maual Treatment (MMT)
D: Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Child/Adolescent Anxiety Multimodal Treatment Study
Brief Summary: This randomized, controlled trial compared the efficacy of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders.


Options:
A: Arm Label: Cognitive Behavioral Therapy Condition; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy Condition | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: 1. Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: 2. Client Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1. Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2. Client Centered Therapy
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
D: Arm Label: Sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT) | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: SRT + CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline (SRT), Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline (SRT); Assigned to Arm(s): SRT + CBT, Sertraline | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT, SRT + CBT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PST in Geriatric Depression With Executive Dysfunction
Brief Summary: This study will compare the effectiveness of Problem Solving Therapy and Brief Supportive Therapy in treating elderly patients with major depression and thought problems.


Options:
A: Arm Label: Interpersonal Psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Psychoeducational Group Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Psychotherapy, Behavioral: Psychoeducational Group Therapy | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy | Intervention Type: BEHAVIORAL; Name: Psychoeducational Group Therapy; Assigned to Arm(s): Interpersonal Psychotherapy, Psychoeducational Group Therapy
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: desvenlafaxine succinate sustained release | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Genetic: Genotyping | Intervention Type: DRUG; Name: desvenlafaxine succinate sustained release; Assigned to Arm(s): 1 | Intervention Type: GENETIC; Name: Genotyping; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PST in Geriatric Depression With Executive Dysfunction
Brief Summary: This study will compare the effectiveness of Problem Solving Therapy and Brief Supportive Therapy in treating elderly patients with major depression and thought problems.


Options:
A: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3
C: Intervention Type: BEHAVIORAL; Name: support groups; Assigned to Arm(s): N/A
D: Arm Label: Behavior Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation (BA) | Arm Label: Supportive Therapy (ST); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy (ST) | Intervention Type: BEHAVIORAL; Name: Behavioral Activation (BA); Assigned to Arm(s): Behavior Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy (ST); Assigned to Arm(s): Supportive Therapy (ST)

Answer: A